ATE431396T1 - Für hcv-infektion geeignete zusammensetzungen und verfahren - Google Patents

Für hcv-infektion geeignete zusammensetzungen und verfahren

Info

Publication number
ATE431396T1
ATE431396T1 AT02753872T AT02753872T ATE431396T1 AT E431396 T1 ATE431396 T1 AT E431396T1 AT 02753872 T AT02753872 T AT 02753872T AT 02753872 T AT02753872 T AT 02753872T AT E431396 T1 ATE431396 T1 AT E431396T1
Authority
AT
Austria
Prior art keywords
compositions
hcv
methods
hcv infection
methods suitable
Prior art date
Application number
AT02753872T
Other languages
English (en)
Inventor
Ann Kwong
Randal Byrn
Lola Reid
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE431396T1 publication Critical patent/ATE431396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/18—Liver cell growth factor (LCGF, Gly-His-Lys)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/375—Thyroid stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Semiconductor Lasers (AREA)
AT02753872T 2001-03-27 2002-03-27 Für hcv-infektion geeignete zusammensetzungen und verfahren ATE431396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27917401P 2001-03-27 2001-03-27
PCT/US2002/009685 WO2002077206A1 (en) 2001-03-27 2002-03-27 Compositiona and methods useful for hcv infection

Publications (1)

Publication Number Publication Date
ATE431396T1 true ATE431396T1 (de) 2009-05-15

Family

ID=23067944

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02753872T ATE431396T1 (de) 2001-03-27 2002-03-27 Für hcv-infektion geeignete zusammensetzungen und verfahren

Country Status (14)

Country Link
US (3) US7879606B2 (de)
EP (1) EP1381673B1 (de)
JP (2) JP4499990B2 (de)
KR (1) KR100947911B1 (de)
CN (1) CN100362095C (de)
AT (1) ATE431396T1 (de)
CA (1) CA2441688C (de)
DE (1) DE60232322D1 (de)
ES (1) ES2328466T3 (de)
MX (1) MXPA03008882A (de)
NO (1) NO20034278L (de)
NZ (1) NZ528462A (de)
WO (1) WO2002077206A1 (de)
ZA (1) ZA200307373B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100509388B1 (ko) 1996-10-18 2005-08-23 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP2031070B1 (de) 2002-12-04 2013-07-17 Life Technologies Corporation Multiplexverstärkung von Polynucleotiden
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
CN1910275B (zh) * 2003-12-01 2011-04-27 威特克斯医药股份有限公司 包含胎儿肝细胞的组合物及其用于hcv感染的方法
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP1991229A2 (de) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Kokristalle und pharmazeutische zusammensetzungen damit
EP1993994A2 (de) 2006-03-16 2008-11-26 Vertex Pharmceuticals Incorporated Deuterierte hepatitis-c-protease-hemmer
DK2114924T3 (da) 2007-02-27 2012-04-10 Vertex Pharma Co-krystaller og farmaceutiske sammensætninger omfattende disse
JP2010519329A (ja) 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤
CN101835774B (zh) 2007-08-30 2014-09-17 弗特克斯药品有限公司 共晶体和包含该共晶体的药物组合物
WO2009073689A1 (en) 2007-12-04 2009-06-11 Miladin Kostovic Kit and method for detecting bovine viral diarrhea virus in tissue samples
CN101906487A (zh) * 2010-08-05 2010-12-08 中国兽医药品监察所 一种猪瘟病毒核酸标准物质的制备方法
KR102089477B1 (ko) * 2012-08-31 2020-03-17 더 가버너스 오브 더 유니버시티 오브 알버타 1차 인간 간세포의 표현형을 갖는 세포를 생성하기 위한 방법 및 조성물
WO2016174130A1 (en) 2015-04-28 2016-11-03 Université De Strasbourg Clinical gene signature-based human cell culture model and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529920A (en) * 1988-12-14 1996-06-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human liver epithelial cell line and culture media therefor
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
WO1993003142A1 (en) 1991-08-07 1993-02-18 Albert Einstein College Of Medicine Proliferation of hepatocyte precursors
US6069005A (en) 1991-08-07 2000-05-30 Albert Einstein College Of Medicine Of Yeshwa University Hapatoblasts and method of isolating same
ES2260759T3 (es) 1993-11-19 2006-11-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hepatoblastos y metodo de aislamiento de los mismos.
CN1122531C (zh) * 1995-08-01 2003-10-01 巴斯德梅诺血清和疫苗公司 抗日本脑炎疫苗的工业生产方法和所获得的疫苗
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
CA2217266A1 (en) * 1997-05-14 1998-11-14 The General Hospital Corporation Co-cultivation of cells in a micropatterned configuration
FR2775983B1 (fr) * 1998-03-13 2000-11-10 Pasteur Merieux Serums Vacc Milieu et procede de propagation et de multiplication virales
EP0972828A1 (de) * 1998-06-24 2000-01-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verfahren zur in vitro Replikation von HCV
DK1975243T3 (da) * 1998-12-07 2010-06-28 Univ Duke BODIPY-aminoacetaldehyddiethylacetal
AU779706B2 (en) 1999-01-19 2005-02-10 University Of North Carolina At Chapel Hill, The Human liver progenitors
US20020187133A1 (en) 1999-10-01 2002-12-12 Hiroshi Kubota Methods of isolating bipotent hepatic progenitor cells
WO2001053462A1 (en) 2000-01-19 2001-07-26 University Of North Carolina At Chapel Hill Liver tissue source
CN1461341A (zh) 2000-10-03 2003-12-10 北卡罗来纳大学 肝祖先细胞克隆生长的方法
CN1258589C (zh) 2000-10-03 2006-06-07 北卡罗来纳大学 分离双能肝祖细胞的方法
WO2002072776A2 (en) 2001-03-09 2002-09-19 The Regents Of The University Of California Cell culture system for synthesis of infectious hepatitis c virus
WO2004003172A2 (en) * 2002-07-01 2004-01-08 Pharmacia Corporation Esm-1 gene differentially expressed in angiogenesis, antagonists thereof, and methods of using the same

Also Published As

Publication number Publication date
US20020142449A1 (en) 2002-10-03
JP2004529637A (ja) 2004-09-30
EP1381673B1 (de) 2009-05-13
ZA200307373B (en) 2005-06-29
NO20034278L (no) 2003-11-25
MXPA03008882A (es) 2003-12-08
NZ528462A (en) 2005-11-25
US7879606B2 (en) 2011-02-01
DE60232322D1 (de) 2009-06-25
KR20040012739A (ko) 2004-02-11
CN1511190A (zh) 2004-07-07
HK1063334A1 (en) 2004-12-24
CA2441688A1 (en) 2002-10-03
EP1381673A4 (de) 2004-11-10
JP4499990B2 (ja) 2010-07-14
CN100362095C (zh) 2008-01-16
WO2002077206A9 (en) 2004-02-19
JP2010142249A (ja) 2010-07-01
US20130071834A1 (en) 2013-03-21
WO2002077206A1 (en) 2002-10-03
NO20034278D0 (no) 2003-09-25
CA2441688C (en) 2014-01-21
US20110229874A1 (en) 2011-09-22
US8211696B2 (en) 2012-07-03
EP1381673A1 (de) 2004-01-21
ES2328466T3 (es) 2009-11-13
KR100947911B1 (ko) 2010-03-17

Similar Documents

Publication Publication Date Title
ATE431396T1 (de) Für hcv-infektion geeignete zusammensetzungen und verfahren
DE60232234D1 (de) Verfahren zur kultivierung von circovirus
ATE419388T1 (de) Nukleinsäureanreicherung
DE60234464D1 (de) Zusammensetzungen und Verfahren zur selektiven Nukleinsäureisolierung
DE602006017365D1 (de) Zusammensetzungen für die identifizierung von adenoviren
WO2006116127A3 (en) Compositions for use in identification of bacteria
ECSP045255A (es) Cumarinas utiles como biomarcadores
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
ATE469219T1 (de) Zusammensetzungen, methoden und reagentien zur nukleinsäureisolierung mittels oberflächenaktiven substanzen und proteasen
ATE461990T1 (de) Zusammensetzung für die gewebepflege
DE602004030372D1 (de) Verfahren zur Bestimmung des relativen genetischen Risikos für Autismus
ECSP066467A (es) Formas Polimórficas de 3-(4-amino-1-Oxo-1-3 DIhidroisoindol-2-IL)-Piperidin-2,6-Diona
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
TW200732349A (en) Anti-OX40L antibodies and methods using same
TW200619287A (en) Composition and method
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
WO2010042551A3 (en) Methods for providing cellular lysates from cell wall-containing samples
SG148182A1 (en) Antiloading compositions and methods of selecting same
DE102005053064A1 (de) Verfahren zur Herstellung von Pfropfpolymerisaten
DE602005019156D1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
ATE406461T1 (de) Rna-bioassay
TW200716130A (en) Purified form of tanaproget
ATE514793T1 (de) Zusammensetzungen und verfahren für il13- biomarker
ATE420162T1 (de) Verfahren und zusammensetzungen zum targeting sekretorischer lysosomen
ATE449838T1 (de) Verfahren für donorspezifisches crossmatching

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties